Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pharvaris N.V. (NQ: PHVS ) 18.36 +0.29 (+1.60%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 43,622 Open 18.00 Bid (Size) 7.260 (2) Ask (Size) 28.67 (1) Prev. Close 18.07 Today's Range 17.83 - 18.90 52wk Range 14.35 - 33.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily Pharvaris Announces Annual Meeting of Shareholders June 11, 2024 From Pharvaris N.V. Via GlobeNewswire Performance YTD -29.03% -29.03% 1 Month -4.97% -4.97% 3 Month -0.33% -0.33% 6 Month -35.71% -35.71% 1 Year +16.42% +16.42% More News Read More Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses May 13, 2024 From Pharvaris N.V. Via GlobeNewswire Analyst Expectations for Pharvaris's Future December 07, 2023 Via Benzinga Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses June 04, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 May 08, 2024 Via InvestorPlace Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 April 10, 2024 Via InvestorPlace Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 10, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer April 10, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference April 04, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses March 18, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses March 06, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 March 05, 2024 From Pharvaris N.V. Via GlobeNewswire Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting February 22, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Extraordinary Meeting of Shareholders February 16, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present at the WSAAI Annual Meeting 2024 January 26, 2024 From Pharvaris N.V. Via GlobeNewswire Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision January 22, 2024 Via Investor's Business Daily Exposures Product Safety FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps January 22, 2024 Via Benzinga Exposures Product Safety Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks January 22, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities January 05, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 December 08, 2023 From Pharvaris N.V. Via GlobeNewswire Gold Moves Higher; Campbell Soup Earnings Top Expectations December 06, 2023 Via Benzinga Topics Stocks Exposures US Equities Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session December 06, 2023 Via Benzinga Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks December 06, 2023 Via Benzinga Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
